Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

Pfizer is expected to post fourth-quarter adjusted earnings of 57 cents a share on revenue of $16.85 billion, according to analysts polled by FactSet. That compares with adjusted earnings of 63 cents ...

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

Pfizer (NYSE:PFE) has entered a non exclusive licensing agreement with Novavax for access to its Matrix-M adjuvant technology. The company is also participating in the White House TrumpRx initiative, ...

Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-loss ...

Jan 27 (Reuters) - The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major pharmaceutical companies including Eli Lilly, Pfizer and AbbVie for the ...

The patent cliff looms large. UBS analyst Michael Yee pointed to roughly "$15-20B in revenues from key drugs losing patent exclusivity" over the next three years, including blockbusters Vyndaquel, ...

Months after it agreed to hold off on raising prices following heavy pressure from President Trump, Pfizer now says it will increase the prices of 41 drugs in January. The pharmaceutical giant says ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he ...